Navigation Links
EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
Date:11/16/2009

ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. ( ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of data for the Phase 1 study for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, in leukemia patients. The Company also announced that it has selected ovarian cancer as an initial Phase 2 indication.

Phase 1 Leukemia Data

Initial data for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in Boston, Massachusetts. Early results for the study in hematological cancers demonstrated that ENMD-2076, administered orally as a single agent, was well tolerated. Data for 15 evaluable patients showed that one patient achieved a CRi (complete remission with incomplete hematological recovery) and two patients achieved a morphologic leukemia-free state (MLFS). Three additional patients experienced 11%, 14%, and 65% reductions in marrow blast count. The AML study continues to enroll patients and pharmacodynamic and pharmacokinetic activity is being monitored.

Ovarian Cancer - Initial Phase 2 Indication

While early Phase 1 data from the leukemia study are encouraging, the Company has selected ovarian cancer as its initial Phase 2 indication. This decision is supported by data from the ongoing Phase 1 study with ENMD-2076 in patients with solid tumors where of the 20 ovarian cancer patients, tumor and tumor marker responses were demonstrated in 45% of patients. In addition, another 15% have shown clinical benefit including reductions in tumor size, improvement in symptoms, or both. The decision is further supported by robust preclinical data and the need for additional active age
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
2. EntreMed Presents Initial Clinical Results for ENMD-2076
3. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National Active Lifestyle Skincare Destinations
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
8. MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D
9. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
10. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
11. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , LAS ANGELES, ... that it would initiate a programme of,regular updates to shareholders, ... in the fulfilment of its business plan, as,well as to ... Dunn Capital Partners and others. , ...
... , CENTENNIAL, Colo., Dec. 2 AlloSource, one of the ... allografts for use in surgical procedures and the world,s largest ... sponsorship of a truly iconic symbol of hope as a ... January 1, 2010 Tournament of Roses Parade®. Manuel Salazar, ...
Cached Medicine Technology:Fountain Healthy Aging Inc Business Update For Shareholders 2Fountain Healthy Aging Inc Business Update For Shareholders 3AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... the open access journal BMC Medicine has found that the ... in India are flawed and the actual number of cases ... are from the Administrative Staff College of India, conducted the ... Medical Sciences in Hyderabad. ,According to the ...
... of his family served in the Indian Army and battled the ... Sena Medal winner// and with ‘Showrya’ meaning ‘brave’ for a name, ... family path. ,But a fall from the first floor ... the one-and-a-half-year-old Showrya Malik, who was pronounced ‘brain dead’ the next ...
... Pradesh government is considering setting up a medical and health ... Health Minister Ajay Vishnoi said Tuesday. ,"The government ... Medical Council of India for opening the university," Vishnoi told ... workshop on Indian medical systems. ,"The need ...
... are not protected from attacks or stroke by taking a ... ,Folic acid or folate is one of the B Vitamins ... medical practitioners prescribe it to prevent cardiac problems. ... Health and Tropical Medicine, New Orleans led a research on ...
... damaging to health, but obesity has higher damaging properties, ... cancers reducing a person’s life span by seven years ... ,Ken Snider, advisor at NICE i.e. National Institute for ... not only to do with weight loss but also ...
Cached Medicine News:Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:A ‘Brave’ Toddler-The Youngest Organ Don 2Health News:Ways to Fight Childhood Obesity 2
... Vitrectomy Lenses are a family of single-use direct ... of a particular region of the retinal surface ... less than 1 gram and is formed and ... of a human cornea. Lenses come in boxes ...
... The AFX Lens is a ... use in an air-filled eye. ... as a primary air-fluid exchange ... and sutureless design make it ...
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
Medicine Products: